MX338914B - Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. - Google Patents
Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.Info
- Publication number
- MX338914B MX338914B MX2012013286A MX2012013286A MX338914B MX 338914 B MX338914 B MX 338914B MX 2012013286 A MX2012013286 A MX 2012013286A MX 2012013286 A MX2012013286 A MX 2012013286A MX 338914 B MX338914 B MX 338914B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- amino acid
- random coil
- biosynthetic
- proline
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 19
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 19
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 19
- 230000001851 biosynthetic effect Effects 0.000 title abstract 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title abstract 6
- 235000004279 alanine Nutrition 0.000 title abstract 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 235000018102 proteins Nutrition 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 229940126586 small molecule drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C07K14/615—Extraction from natural sources
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Dermatology (AREA)
Abstract
La presente invención se refiere a un polipéptido biosintético de espira aleatoria o un segmento del polipéptido biosintético de espira aleatoria o conjugado biosintético, en donde el polipéptido biosintético de espira aleatoria, el segmento del polipéptido biosintético de espira aleatoria o el conjugado biosintético comprende una secuencia de aminoácidos que consiste únicamente de residuos de aminoácidos de prolina y alanina, en donde la secuencia de aminoácidos consiste de al menos aproximadamente 50 residuos de aminoácidos de prolina (Pro) y alanina (Ala). Al menos aproximadamente 50 residuos de aminoácidos de prolina (Pro) y alanina (Ala) pueden ser los constituyentes de un polipéptido heterólogo o un constructo de un polipéptido heterólogo. También se describen los usos y métodos de uso de estos polipéptidos biosintéticos de espira aleatoria o los segmentos de polipéptido o conjugados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10163564 | 2010-05-21 | ||
US201061428016P | 2010-12-29 | 2010-12-29 | |
PCT/EP2011/058307 WO2011144756A1 (en) | 2010-05-21 | 2011-05-20 | Biosynthetic proline/alanine random coil polypeptides and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012013286A MX2012013286A (es) | 2013-03-05 |
MX338914B true MX338914B (es) | 2016-05-06 |
Family
ID=42629445
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005860A MX357674B (es) | 2010-05-21 | 2011-05-20 | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. |
MX2012013286A MX338914B (es) | 2010-05-21 | 2011-05-20 | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005860A MX357674B (es) | 2010-05-21 | 2011-05-20 | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. |
Country Status (19)
Country | Link |
---|---|
US (3) | US9221882B2 (es) |
EP (2) | EP3473261A1 (es) |
JP (2) | JP5828889B2 (es) |
KR (1) | KR101872541B1 (es) |
CN (2) | CN105477641B (es) |
AU (1) | AU2011254564B2 (es) |
BR (1) | BR112012029577B1 (es) |
CA (1) | CA2794614C (es) |
DK (1) | DK2571510T3 (es) |
EA (1) | EA024755B1 (es) |
ES (1) | ES2691642T3 (es) |
HK (1) | HK1219902A1 (es) |
LT (1) | LT2571510T (es) |
MX (2) | MX357674B (es) |
NZ (1) | NZ602522A (es) |
PL (1) | PL2571510T3 (es) |
SG (1) | SG185440A1 (es) |
SI (1) | SI2571510T1 (es) |
WO (1) | WO2011144756A1 (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2571510T1 (sl) | 2010-05-21 | 2019-02-28 | Xl-Protein Gmbh | Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe |
EP2741782B1 (en) * | 2011-08-12 | 2020-05-06 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
SG11201405276PA (en) | 2012-02-27 | 2014-10-30 | Amunix Operating Inc | Xten conjugate compositions and methods of making same |
EA031986B1 (ru) | 2012-04-04 | 2019-03-29 | Галозим, Инк. | Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию |
US10066007B2 (en) * | 2013-01-22 | 2018-09-04 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
JP6259207B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | エラスチン産生促進剤 |
JP6259208B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | ヒアルロン酸産生促進剤 |
JP6259209B2 (ja) * | 2013-06-17 | 2018-01-10 | 雪印メグミルク株式会社 | コラーゲン産生促進剤 |
AU2014345511A1 (en) | 2013-11-11 | 2016-05-12 | Ascendis Pharma A/S | Relaxin prodrugs |
US9618507B2 (en) | 2014-02-24 | 2017-04-11 | Betanien Hospital | Methods of treating rheumatoid arthritis |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
PL228341B1 (pl) * | 2014-04-21 | 2018-03-30 | Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia | Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu |
WO2016030334A2 (en) * | 2014-08-26 | 2016-03-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
EP3220892B1 (en) | 2014-11-21 | 2021-10-13 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
ES2784603T3 (es) | 2015-06-02 | 2020-09-29 | Novo Nordisk As | Insulinas con extensiones recombinantes polares |
TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
US10789711B2 (en) * | 2015-09-09 | 2020-09-29 | Technische Universiteit Eindhoven | Imaging of dispersion and velocity of contrast agents |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
JP7098519B2 (ja) * | 2015-10-08 | 2022-07-11 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | C型肝炎ウイルスe1/e2ヘテロダイマー及びそれを生成する方法 |
SI3394266T1 (sl) * | 2015-12-22 | 2021-08-31 | Xl-Protein Gmbh | Nukleinske kisline, ki kodirajo ponavljajoča se aminokislinska zaporedja, bogata s prolinskimi in alaninskimi ostanki, ki imajo manj ponavljajočih se nukleotidnih zaporedij |
WO2017112889A1 (en) | 2015-12-23 | 2017-06-29 | The Johns Hopkins University | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions |
WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
EP3400022A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
BR112018011008A2 (pt) | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com ligação a npr-c baixa |
WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
US11078472B2 (en) | 2016-01-20 | 2021-08-03 | Merz Pharma Gmbh & Co., Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
JP7059195B2 (ja) | 2016-03-01 | 2022-04-25 | アセンディス ファーマ ボーン ディジージズ エー/エス | Pthプロドラッグ |
CA3010146A1 (en) | 2016-03-02 | 2017-09-08 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
WO2017173346A1 (en) * | 2016-04-01 | 2017-10-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Par3 mimetic peptides and uses thereof |
WO2017191252A1 (en) * | 2016-05-04 | 2017-11-09 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
WO2018060311A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
KR20230170810A (ko) | 2016-09-29 | 2023-12-19 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
KR20240013849A (ko) | 2016-09-29 | 2024-01-30 | 아센디스 파마 본 디지즈 에이/에스 | 조절 방출 pth 화합물을 위한 투여 용법 |
JP2019535321A (ja) * | 2016-11-16 | 2019-12-12 | オークランド ユニサービシーズ リミティド | タンパク質ライゲーションの方法及びその使用 |
US11471537B2 (en) | 2017-04-05 | 2022-10-18 | Novo Nordisk A/S | Oligomer extended insulin-Fc conjugates |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
US10174302B1 (en) * | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
AU2018287145B2 (en) * | 2017-06-21 | 2024-04-18 | Jazz Pharmaceuticals Ireland Limited | Modified L-asparaginase |
EP3641827A1 (en) * | 2017-06-21 | 2020-04-29 | XL-protein GmbH | Conjugates of protein drugs and p/a peptides |
EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
EP3483619A1 (en) * | 2017-11-13 | 2019-05-15 | Technische Universität München | Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg |
US20200354706A1 (en) * | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
US20190184028A1 (en) * | 2017-12-14 | 2019-06-20 | Janssen Biotech, Inc. | Targeting with firbronectin type iii like domain molecules |
GB201804092D0 (en) * | 2018-03-14 | 2018-04-25 | Imperial Innovations Ltd | Methods and compositions |
SG11202007524QA (en) | 2018-03-28 | 2020-09-29 | Ascendis Pharma Oncology Div A/S | Il-2 conjugates |
US20210008168A1 (en) | 2018-03-28 | 2021-01-14 | Ascendis Pharma A/S | Conjugates |
TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
SG11202010387QA (en) | 2018-05-18 | 2020-11-27 | Ascendis Pharma Bone Diseases As | Starting dose of pth conjugates |
WO2020069398A1 (en) | 2018-09-27 | 2020-04-02 | Akrevia Therapeutics Inc. | Masked cytokine polypeptides |
CN113396158A (zh) | 2018-11-26 | 2021-09-14 | 诺华股份有限公司 | Lpl-gpihbp1融合多肽 |
CA3137395A1 (en) * | 2019-01-10 | 2020-07-16 | Roswell Biotechnologies Inc. | Conductive synthetic peptides for molecular electronics |
JP2022520193A (ja) | 2019-02-11 | 2022-03-29 | アセンディス ファーマ グロース ディスオーダーズ エー/エス | Cnpコンジュゲートの乾燥医薬製剤 |
CN113423383A (zh) | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
CA3131817A1 (en) | 2019-03-04 | 2020-09-10 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
EP3714909A1 (en) * | 2019-03-28 | 2020-09-30 | Industrie Biomediche Insubri S.A. | Improved bone implant matrix comprising proline-rich peptide and method of preparing the same |
US10784093B1 (en) * | 2019-04-04 | 2020-09-22 | Thermo Finnigan Llc | Chunking algorithm for processing long scan data from a sequence of mass spectrometry ion images |
AU2020296297A1 (en) | 2019-06-21 | 2021-12-16 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
US20220304993A1 (en) | 2019-06-21 | 2022-09-29 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
WO2020254603A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS |
CA3152665A1 (en) | 2019-08-27 | 2021-03-04 | Tonix Pharma Limited | Modified tff2 polypeptides |
US20230002447A1 (en) * | 2019-12-03 | 2023-01-05 | Rodan & Fields, Llc | Peptides and compositions for inhibiting hair growth |
AU2020419444A1 (en) | 2020-01-03 | 2022-06-09 | Ascendis Pharma A/S | Conjugates undergoing intramolecular rearrangements |
JP2023510790A (ja) | 2020-01-13 | 2023-03-15 | アセンディス ファーマ ボーン ディジージズ エー/エス | 副甲状腺機能低下症の治療 |
CN113527485A (zh) * | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
GB202007106D0 (en) * | 2020-05-14 | 2020-07-01 | Ucl Business Plc | Cyclosporine analogues |
AU2021286177A1 (en) | 2020-06-03 | 2022-12-01 | Ascendis Pharma Oncology Division A/S | IL-2 sequences and uses thereof |
WO2022029178A1 (en) | 2020-08-05 | 2022-02-10 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
AU2021349316A1 (en) | 2020-09-28 | 2023-04-27 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
EP4267628A1 (en) | 2020-12-22 | 2023-11-01 | XL-protein GmbH | Antibodies specific for structurally disordered sequences |
CN112843222B (zh) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用 |
AU2022246997A1 (en) | 2021-04-01 | 2023-09-28 | Ascendis Pharma A/S | Use of long-acting growth hormone for treating inflammation-induced diseases |
CA3230895A1 (en) | 2021-09-22 | 2023-03-30 | Kennett Sprogoe | Long-acting pth compound treatments |
AU2022413318A1 (en) | 2021-12-13 | 2024-05-16 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
WO2024094673A1 (en) | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI92601C (fi) | 1992-03-11 | 1994-12-12 | Marja Makarow | Menetelmä hyötyproteiinien erittämiseksi hiivoista |
US6639050B1 (en) * | 1997-07-21 | 2003-10-28 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
AU2001267337A1 (en) | 2000-06-30 | 2002-01-14 | Maxygen Aps | Peptide extended glycosylated polypeptides |
US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
US20060252120A1 (en) * | 2003-05-09 | 2006-11-09 | Kieliszewski Marcia J | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
EP1734994A1 (en) | 2004-03-15 | 2006-12-27 | Trimeris, Inc. | Site-specific chemical modification of hiv gp41-derived peptides |
US8221969B2 (en) * | 2004-04-19 | 2012-07-17 | Sanyo Chemical Industries, Ltd. | Method of producing virus |
JP5735194B2 (ja) | 2005-01-25 | 2015-06-17 | セル セラピューティクス インコーポレーテッド | 改善された生体内半減期を有する生物学的に活性なタンパク質 |
WO2007103455A2 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
US20100203083A1 (en) * | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
NZ580670A (en) * | 2007-06-21 | 2011-09-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
EP2393828B1 (en) | 2009-02-03 | 2016-10-12 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
MX354555B (es) | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. |
SI2571510T1 (sl) | 2010-05-21 | 2019-02-28 | Xl-Protein Gmbh | Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe |
-
2011
- 2011-05-20 SI SI201131597T patent/SI2571510T1/sl unknown
- 2011-05-20 ES ES11725656.0T patent/ES2691642T3/es active Active
- 2011-05-20 US US13/697,569 patent/US9221882B2/en active Active
- 2011-05-20 MX MX2016005860A patent/MX357674B/es unknown
- 2011-05-20 JP JP2013510644A patent/JP5828889B2/ja active Active
- 2011-05-20 BR BR112012029577-2A patent/BR112012029577B1/pt active IP Right Grant
- 2011-05-20 WO PCT/EP2011/058307 patent/WO2011144756A1/en active Application Filing
- 2011-05-20 NZ NZ602522A patent/NZ602522A/en unknown
- 2011-05-20 EA EA201291010A patent/EA024755B1/ru unknown
- 2011-05-20 EP EP18184601.5A patent/EP3473261A1/en not_active Withdrawn
- 2011-05-20 KR KR1020127030156A patent/KR101872541B1/ko active IP Right Grant
- 2011-05-20 PL PL11725656T patent/PL2571510T3/pl unknown
- 2011-05-20 DK DK11725656.0T patent/DK2571510T3/en active
- 2011-05-20 CN CN201510649876.3A patent/CN105477641B/zh active Active
- 2011-05-20 MX MX2012013286A patent/MX338914B/es active IP Right Grant
- 2011-05-20 EP EP11725656.0A patent/EP2571510B1/en active Active
- 2011-05-20 CA CA2794614A patent/CA2794614C/en active Active
- 2011-05-20 LT LTEP11725656.0T patent/LT2571510T/lt unknown
- 2011-05-20 SG SG2012081733A patent/SG185440A1/en unknown
- 2011-05-20 CN CN201180022849.3A patent/CN102883734B/zh active Active
- 2011-05-20 AU AU2011254564A patent/AU2011254564B2/en active Active
-
2015
- 2015-07-31 JP JP2015152081A patent/JP6038248B2/ja active Active
- 2015-11-12 US US14/939,626 patent/US10081657B2/en active Active
-
2016
- 2016-07-11 HK HK16108081.5A patent/HK1219902A1/zh unknown
-
2018
- 2018-08-21 US US16/107,590 patent/US10844094B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX338914B (es) | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. | |
EA021222B8 (ru) | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro | |
Gunasekera et al. | Backbone cyclization and dimerization of LL-37-derived peptides enhance antimicrobial activity and proteolytic stability | |
IN2012DN02981A (es) | ||
EP2520590A3 (en) | Cross-species-specific binding domain | |
BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
MY177065A (en) | 4-1bb binding molecules | |
EA201170635A1 (ru) | Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii | |
MX348360B (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
WO2008119565A3 (en) | Cross-species-specific binding domain | |
MX2012002216A (es) | Nueva endolisina obpgplys. | |
EP2829550A3 (en) | Fusion proteins forming trimers | |
EP2573110A3 (en) | Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens | |
IL192131A0 (en) | Peptides useful as cell-penetrating peptides | |
WO2010150233A3 (en) | Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof | |
ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
EA201490379A1 (ru) | Варианты белков axmi205 и способы их применения | |
Wang et al. | Unnatural amino acids: Promising implications for the development of new antimicrobial peptides | |
EA202091496A1 (ru) | Вариант инсектицидного гена axmi115 и способы его применения | |
WO2012126118A8 (en) | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy | |
WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
JP2013249272A (ja) | 皮膚弾性向上材及び皮膚弾性向上用タンパク質溶液 | |
EP3372617A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: XL-PROTEIN GMBH.* |
|
FG | Grant or registration |